David M. O’Malley, MD, discusses final analysis data from the phase 1b FORWARD II trial of mirvetuximab soravtansine plus bevacizumab as treatment of patients with platinum-agnostic ovarian cancer.
Joshua K. Sabari, MD, reviews the therapies available to treat patients with EGFR exon 20-positive non–small cell lung cancer.
The panel of experts in breast cancer discuss enrollment of patients with TNBC in clinical trials, including considerations and barriers.
Experts in the field of breast cancer review the role of genetic testing in the selection of treatment for patients with TNBC.
Ruta Rao, MD, discusses practical considerations regarding the use of sacituzumab govitecan in patients with relapsed/refractory TNBC.
The panel of experts share their treatment recommendations for patients with residual disease after an incomplete response to TNBC therapy.
Pathologist David G. Hicks, MD, discusses the impact of residual disease in breast cancer treatment outcomes.
Elizabeth Mittendorf, MD, PhD, and Ruta Rao, MD, present the case of a 48-year-old woman with stage T2N1 TNBC.
Kathleen Moore, MD, discusses the safety and efficacy profile of niraparib, based on data from the phase 3 trials, PRIMA; ENGOT-OV16/NOVA, and NORA.
Efstathios Kastritis, MD, discusses the amyloidosis setting, current standards of care, and the phase 3 ANDROMEDA trial.
Jamie E. Chaft, MD, discusses the background behind the phase 3 GEMSTONE-302 trial of platinum-based chemotherapy with placebo or CS1001 as front-line treatment for patients with advanced non-small cell lung cancer.
Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the safety profile of amivantamab and lazertinib in EGFR-mutated non-small cell lung cancer, based on data from the CHRYSALIS tria.
Jorge Nieva, MD, discusses the backgroup to the IMpower010 study, the results of which were presented at the 2021 American Society of Clinical Oncology Annual Meeting.
Ursula A. Matulonis, MD, the chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute, explains how the treatment paradigm of ovarian cancer has evolved with abundance of PARP inhibitors.
Carey Anders, MD, presents a case that focuses on a patient with HER2+ breast cancer and brain metastases.
Experts in the field of breast cancer review the place in therapy for margetuximab.
Experts in the management of breast cancer review clinical trial data using PARP inhibitors in the treatment of BRCA1/2-mutated TNBC.
The panel of experts in breast cancer discusses the treatment options for a patient with systemic progression of HER2+ disease on T-DM1 and no CNS metastases.
Experts in the management of breast cancer discuss the role of tucatinib in patients with brain metastases.
Experts in the management of breast cancer review some treatment considerations surrounding the use of PARP inhibitors in BRCA1/2–positive triple-negative breast cancer.
Elizabeth Mittendorf, MD, PhD, presents the case of a 34-year-old woman with PD-L1–positive triple-negative breast cancer.
Expert hematologist/oncologists provide thoughts on the potential role of PI3K inhibitors in managing R/R FL and MZL, as well as other diseases.
Ian W. Flinn, MD, PhD, and Jason M. Melear, MD, discuss the role of PI3K inhibitor combination therapy and novel agents on the horizon for the treatment of R/R FL and MZL.
Amit Singal, MD, discusses options after surgical resection for patients with hepatocellular carcinoma.
Michael Bishop, MD, discusses the different settings where chimeric antigen receptor T-cell therapy are used.
Joshua K. Sabari, MD, discusses the need for EGFR inhibitors designed specifically to treat patients with EGFR-mutant non–small cell lung cancer and an exon 20 insertion.
Jared Weiss, MD, shares insight into current unmet needs in extensive-stage small cell lung cancer and provides advice to researchers about the importance of clinical trials studying differential treatments and biomarkers.
Expert oncologist Jared Weiss, MD, considers safety and efficacy data from the ATLANTIS study of lurbinectedin in combination with doxorubicin in relapsed small cell lung cancer.
Thought leader in lung cancer, Jared Weiss, MD, reviews safety and efficacy data from the phase 2 basket trial of lurbinectedin in selected advanced solid tumors.
Key opinion leader in thoracic oncology, Jared Weiss, MD, discusses the role of second-line treatment for relapsed ES-SCLC after first-line therapy and maintenance immunotherapy.